The stock of Inhibikase Therapeutics Inc (NASDAQ: IKT) has decreased by -16.50 when compared to last closing price of 2.97.Despite this, the company has seen a gain of 5.53% in its stock price over the last five trading days. globenewswire.com reported 2025-02-24 that — Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development — — John Adams, PhD Appointed Chief Scientific Officer — — Vince Aurentz to join Inhibikase Board of Directors — BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two pharma industry executives with deep experience in pulmonary arterial hypertension (“PAH”) to its senior leadership team. Chris Cabell, M.D.
Is It Worth Investing in Inhibikase Therapeutics Inc (NASDAQ: IKT) Right Now?
Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for IKT is 42.48M, and currently, short sellers hold a 2.52% ratio of that floaft. The average trading volume of IKT on February 25, 2025 was 280.58K shares.
IKT’s Market Performance
IKT stock saw a decrease of 5.53% in the past week, with a monthly decline of -12.37% and a quarterly a decrease of 24.00%. The volatility ratio for the week is 16.92%, and the volatility levels for the last 30 days are 12.05% for Inhibikase Therapeutics Inc (IKT). The simple moving average for the past 20 days is -0.88% for IKT’s stock, with a 24.47% simple moving average for the past 200 days.
IKT Trading at -13.29% from the 50-Day Moving Average
After a stumble in the market that brought IKT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.95% of loss for the given period.
Volatility was left at 12.05%, however, over the last 30 days, the volatility rate increased by 16.92%, as shares sank -11.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.74% lower at present.
During the last 5 trading sessions, IKT rose by +5.53%, which changed the moving average for the period of 200-days by +92.25% in comparison to the 20-day moving average, which settled at $2.50. In addition, Inhibikase Therapeutics Inc saw -23.69% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IKT starting from Bellini Roberto, who purchase 1,460,000 shares at the price of $1.37 back on Oct 21 ’24. After this action, Bellini Roberto now owns 1,460,000 shares of Inhibikase Therapeutics Inc, valued at $2,000,200 using the latest closing price.
Kush Arvind, the Director of Inhibikase Therapeutics Inc, purchase 145,000 shares at $1.37 during a trade that took place back on Oct 21 ’24, which means that Kush Arvind is holding 145,000 shares at $198,650 based on the most recent closing price.
Stock Fundamentals for IKT
Current profitability levels for the company are sitting at:
- -20063941.0 for the present operating margin
- -19704.0 for the gross margin
The net margin for Inhibikase Therapeutics Inc stands at -19565249.0. The total capital return value is set at 37.81. Equity return is now at value -270.10, with -175.81 for asset returns.
Based on Inhibikase Therapeutics Inc (IKT), the company’s capital structure generated -0.38 points at debt to capital in total, while cash flow to debt ratio is standing at -118.76.
Currently, EBITDA for the company is -19.91 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 171250542.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In a nutshell, Inhibikase Therapeutics Inc (IKT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
